Clinical Trial Results:
            Estudio internacional, multicéntrico, aleatorizado, doble ciego, con grupos paralelos y controlado con placebo del efecto sobre la función cognitiva, la seguridad y la tolerabilidad de SAR110894D, administrado en dosis de 0,5 mg, 2 mg y 5 mg/día durante 24 semanas a pacientes con enfermedad de Alzheimer leve o moderada que reciben tratamiento estable con donepezilo__________________A multinational, multicenter, randomized, double-blind, parallel-group,
placebo-controlled study of the effect on cognitive performance, safety, and tolerability of SAR110894D at the doses of 0.5 mg, 2 mg, and 5 mg/day for 24 weeks in patients with mild to moderate Alzheimer's Disease on stable donepezil therapy
    
|     Summary | |
|     EudraCT number | 2010-022596-64 | 
|     Trial protocol | ES IT PT DE | 
|     Global completion date | 
                                    09 Jan 2013
                             | 
|     Paediatric regulatory details | |
|     Is the trial part of an agreed EMA paediatric investigation plan? | 
                                        No
                                 | 
|     Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? | 
                                        No
                                 | 
|     Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? | 
                                        No
                                 | 
|     Results information | |
|     Results version number | v1(current) | 
|     This version publication date | 
                                    10 May 2016
                             | 
|     First version publication date | 
                                    10 May 2016
                             | 
|     Other versions | |
|     Summary report(s) | DRI10734 | 
            Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to            Commission Guideline 2012/C 302/03
            for further information.    
 
				
